Long non-coding RNA DNMBP-AS1 promotes prostate cancer development by regulating LCLAT1

Yin, Xiaohong; Wang, Suying; Ge, Rong; Chen, Jinping; Gao, Youliang; Xu, Shidang; Yang, Tao

doi:10.1080/19396368.2022.2129520

Cited by 1 publication

(1 citation statement)

References 24 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…It has been hypothesized that the loss of BDNF may explain the loss of neurons where mutant Huntingtin protein is ubiquitously expressed [98,99] . The presence of lncRNA BDNF-AS has been found to decrease the expression and function of the BDNF protein via chromatin modification at the BDNF gene location and thus suppress the expression of the BDNF transcript [100] . Therefore, studying the expression of lncRNA BDNF-AS in HD may be a promising point that can be used for the design of a therapeutic approach for HD.…”

Section: Huntington's Diseasementioning

confidence: 99%

Silent players, loud impact: unveiling the therapeutic potentials of LncRNAs

Kamal,

Swellam,

Shalaby

et al. 2024

J Transl Genet Genom

View full text Add to dashboard Cite

Long non-coding RNAs (lncRNAs) are a class of RNA transcripts that are long (i.e., more than 200 nucleotides) and not translated into proteins. They have recently emerged as potential treatment targets for numerous disorders due to their involvement in multiple cellular functions such as gene regulation, epigenetic modulation, and chromatin organization. This review highlights the current state of lncRNA-based therapeutics, the potential of lncRNAs as drug targets for treating human diseases, the various strategies and types of RNA-based therapeutics, and the complications of developing lncRNA-based drugs. We conclude that lncRNA-based therapeutics represent a promising class of drugs that can potentially treat various human diseases and that further research is needed to fully realize their therapeutic potential.

show abstract

Section: Huntington's Diseasementioning

confidence: 99%